Shareholder rights advocates at levi & korsinsky investigate sana biotechnology, inc. (sana) regarding possible securities fraud violations

New york, ny / accesswire / november 20, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of sana biotechnology, inc. ("sana biotechnology, inc.") (nasdaq:sana) concerning possible violations of federal securities laws. sana issued a press release on november 4, 2024, announcing that it "will suspend development of both sc291 in oncology and of sc379, its glial progenitor cell program, as it seeks partnerships for these programs".
SANA Ratings Summary
SANA Quant Ranking